The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Bristol Myers Squibb competitive analysis

Loading summary...

Latest patents of Bristol Myers Squibb opposed by its competitors

Explore Bristol Myers Squibb's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP3781132
Mar 20, 2024Apixaban Formulations1
EP3818078
Feb 28, 2024Methods Of Producing Recombinant Proteins5
EP3631454
Sep 13, 2023Treatment Of Lag-3 Positive Tumors2
EP3559230
Sep 6, 2023Methods For Increasing The Efficiency Of Homology Directed Repair (Hdr) In The Cellular Genome2
EP3227333
Aug 16, 2023Bispecific Antibodies Against Cd3Epsilon And Bcma For Use In Treatment Of Diseases3
EP3463457
Jun 28, 2023Pd-1 Blockade With Nivolumab In Refractory Hodgkin'S Lymphoma2
EP3464368
Jun 28, 2023Use Of An Anti-Pd-1 Antibody In Combination With An Anti-Cd30 Antibody In Lymphoma Treatment1
EP2508188
May 10, 2023Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate5
EP3464373
Oct 27, 2021Use Of Anti-Pd-1 Antibody In The Treatment Of Patients With Colorectal Cancer6
EP3288980
Mar 10, 2021Treatment Of Pd-L1-Positive Melanoma Using An Anti-Pd-1 Antibody5

Latest PTAB cases involving Bristol Myers Squibb

Discover the latest PTAB cases involving Bristol Myers Squibb, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 15, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Bristol Myers Squibb

IPR2025-00601Feb 28, 2025AMGENBRISTOL MYERS SQUIBBDiscretionary Denial
IPR2025-00602Feb 28, 2025AMGENBRISTOL MYERS SQUIBBDiscretionary Denial
IPR2025-00603Feb 28, 2025AMGENBRISTOL MYERS SQUIBBTerminated
IPR2023-00501Feb 6, 2023DANA FARBER CANCER INSTITUTEBRISTOL MYERS SQUIBBTerminated-Settled
IPR2023-00249Dec 29, 2022DANA FARBER CANCER INSTITUTEBRISTOL MYERS SQUIBBTerminated-Settled
IPR2023-00252Dec 29, 2022DANA FARBER CANCER INSTITUTEBRISTOL MYERS SQUIBBTerminated-Settled
IPR2015-01723Aug 13, 2015COALITION FOR AFFORDABLE DRUGS IXBRISTOL MYERS SQUIBBInstitution Denied
IPR2015-01537Jul 2, 2015MOMENTA PHARMACEUTICALSBRISTOL MYERS SQUIBBFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Bristol Myers Squibb with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BRISTOL MYERS SQUIBB - 67 - 8
GENERICS UK214 - - -
KRAUS & LEDERER PARTGMBB68 - - -
STADA ARZNEIMITTEL11028 - -